Aravive 

Therapies targeting survival pathways for cancer

Aravive, Inc., is a clinical stage biotechnology company focused on developing new therapies that target important survival pathways for both solid tumors as well as hematologic malignancies.

Our primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a critical role in multiple types of malignancies by promoting metastasis and cancer cell survival.

CEO  Gail McIntyre

Advent Contact  Shahzad Malik

Publicly Listed
15 October 2018 in Aravive, Press Release, Publicly Listed

Aravive Biologics and Versartis Complete Merger

Press Release.   October 15, 2018 The combined company, Aravive, Inc., to trade on Nasdaq under ticker symbol “ARAV” beginning October 16, 2018, concurrent with a 1-for-6 reversesplit of common…
Read More